ESMO 2023 – Revolution sets the bar in pan-KRAS inhibition
But efficacy in NSCLC has slipped since the abstract, and a high rate of rash raises eyebrows.
ESMO 2023 – Padcev hits its home run
The presidential session heralds a combo of Padcev and Keytruda as the new front-line bladder cancer standard of care.
Approval milestones – Hutchmed, SpringWorks, Crispr and Ionis eye firsts
A work-stretched US FDA has several key approval application still to review by the end of 2023.
Bicycle aims to follow in Padcev’s slipstream
A study to back accelerated approval is to start next year, but the prospect of seeing a fully greenlit Padcev before then looms large.
ASCO 2023 – Behind Astellas comes Elevation
Elevation’s anti-Claudin18.2 antibody-drug conjugate generates some justified optimism, but Zai Lab’s zolbetuximab challenger is out of luck.
